• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Dermatology Times 2023 In Review: Psoriasis


As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

Union therapeutics is also developing the drug for treatment of atopic dermatitis and hidradenitis suppurativa.

Relationship Between Psoriasis and Food Insecurity Among US Adults

Patients with psoriasis were more likely to receive emergency food from churches, food banks, or soup kitchens.

Managing Difficult Nail Psoriasis and Onychomycosis

Boni E. Elewski, MD, shares her management pearls of how to treat difficult nail psoriasis and onychomycosis at the 2023 Winter Clinical Hawaii Dermatology Conference.

Management of Generalized Pustular Psoriasis

An expert dermatologist reviews generalized pustular psoriasis in 2 patients and how he would approach treatment and management.

Nonsteroidal Treatment Options for Plaque Psoriasis

Linda Stein Gold, MD, and Jennifer Soung, MD, discuss available nonsteroidal treatment options for plaque psoriasis in this DermView series recap.

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

JNJ-2113 met primary endpoints in the FRONTIER 1 clinical trial.

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.

Lipid-Lowering PCSK9 Inhibitors May Reduce Psoriasis Risk

It has been hypothesized that some lipid-lowering drugs are disease-modifying for psoriasis, and the use of lipid-lowering drugs in the management of psoriasis symptoms is currently being explored.

Vitamin D has no Significant Impact on Psoriasis Severity

Oral vitamin D supplementation does not appear to have an effect on disease severity for those with low 25-hydroxyvitamin D (25[OH]D) levels.

FDA Grants Breakthrough Therapy Designation For Spesolimab

The intention is to expedite the development and review of the drug helping adults with generalized pustular psoriasis.

Metabolic Inflammation Contributes to Depression in Psoriatic Disease

As many as 1 in 5 patients with psoriasis experience depression as a comorbidity.

New Study Uncovers Cells and Pathways Driving Psoriasis Inflammation and Severity

Researchers examined the disease while going beyond current diagnostic tools.

Tildrakizumab Improved Sleep, Quality of Life in Patients With Plaque Psoriasis

The IL-23p19 inhibitor demonstrated long-term efficacy and safety.

An Overview of Pediatric Psoriasis

In one-third of cases of psoriasis, disease onset occurs in the first or second decade of life, although it may not be diagnosed until the patient has reached adulthood.

Creating Goals Ahead of Psoriasis Action Month

Melodie Young, MSN, ANP-c, shares pearls on why prioritizing skin checks during Psoriasis Action Month in August is critical.

Generalized Pustular Psoriasis Education Initiative Will Improve Care for Patients

The American Academy of Dermatology’s new project uses AI to take treatment for individuals with generalized pustular psoriasis to the next level.

Cyltezo Biosimilar Launches Today in the US

Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.

Oral Treatment of Plaque Psoriasis Achieves Primary and Secondary Endpoints in Trial

Janssen Pharmaceutical Companies announced its oral treatment for moderate to severe plaque psoriasis will be taken to Phase 3 clinical trials.

Spesolimab Effective in Treating Generalized Pustular Psoriasis Flares

Boehringer Ingelheim announced that novel antibody treatment can interfere in the IL-36 signaling pathway, reducing flares.

Soligenix Expands Synthetic Hypericin Psoriasis Study

Additional patients will be enrolled in the phase 2a study after a clear biological signal was demonstrated in initial participants.

Guselkumab, Ustekinumab Led to 2 Years of Sustained Improvements in Patients With Psoriasis

In the PERSIST study, improvements were sustained through week 104.

Safety Profile of Secukinumab Favorable for Pediatric Patients With Plaque Psoriasis

In subgroups based on age and bodyweight, treatment with secukinumab did not create new safety signals.

CRH-R1 Markedly Increased in Psoriasis, Actinic Keratosis Mast Cells

Investigators noted that there was not a marked increase, however, in keratinocyte skin carcinomas.

Epidermal AXL Expression Lower in Psoriatic Skin

The findings highlight new data on AXL expression in inflammatory diseases.

SFA-002 Phase 1b Trial Shows Positive Results for Treatment of Psoriasis

In the cohort trial, 85% of patients showed an improvement of more than 50 on PASI.

Deucravacitinib: A Year in Review

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

VISIBLE Study Paves Way for More Equitable Psoriasis Research

The study is the only large-scale dermatologic study to prospectively generate insights into skin conditions among patients of racial and ethnic minority groups.

Accurately Recognizing and Diagnosing Psoriasis in Patients With Skin of Color

There may be delays in diagnosis and treatment of psoriasis in patients with darker skin tones due to the clinical presentation variations and less visible erythema.

FDA Delays UCB’s Bimekizumab Approval

FDA action is no longer expected in Q3 of 2023.

Severe Psoriasis Associated With Higher Risk of Heart Disease

Researchers explored the relationship between psoriasis severity and its link to coronary microvascular dysfunction in the largest such study to date.

Discovering Last Month's Psoriasis Spotlight

The September 2023 issue of Dermatology Times featured a spotlight on psoriasis research, advances, and treatment options in patients with skin of color. Learn more about the topics covered in each spotlight article.

FDA Approves Roflumilast Cream 0.3% In Children 6 to 11 Years With PsO

The approval provides pediatric patients with a steroid-free topical therapy.

JNJ-2113 Advances in Clinical Development Programs for Plaque Psoriasis, Ulcerative Colitis

Protagonist Therapeutics has just announced the company's eligibility to receive $60 million of milestone payments for JNJ-2113 to enter into clinical development programs led by Janssen.

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis

Bimekizumab is now the first and only approved IL-17A and IL-17F inhibitor for this indication.

Data From Cohort of Janssen’s VISIBLE Trial Reveals Significant Skin Clearance in PsO Patients With Skin of Color

Topline results from the phase 3b trial revealed significant improvements in patients with skin of color whose psoriasis was treated with guselkumab.

Palmoplantar Psoriasis Risk Increased Among Black and Male Patients

Black and male patients exhibited a higher prevalence of palmoplantar psoriasis when compared with White patients.

World Psoriasis Day Highlights Advocacy, Awareness, and Education

Leah Howard, JD, of the National Psoriasis Foundation, discusses the importance of advocacy in psoriasis, the role of mental health in chronic skin conditions, and the role of support organizations in advocating for awareness and health equity.

FDA Approves Ustekinumab-auub as Interchangeable Biosimilar to Stelara for Plaque Psoriasis, Psoriatic Arthritis, and More

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

Psoriasis Patients With Pruritis, Sleep Impairments Demonstrate Lower Quality of Life in All Domains

PASI scores were significantly correlated with sleep quality, duration, and disturbances.

UCB's Bimekizumab is Now Available

Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.